Electrocardiographic and hemodynamic effects of coenzyme Q10 in healthy individuals: A double-blind, randomized controlled trial

Annals of Pharmacotherapy

Volumn 41, Issue 3, 2007, Pages 420-426

  Shah, Sachin A ^a   Sander, Stephen ^a   Cios, Deborah ^b   Lipeika, Jenny ^b   Kluger, Jeffrey ^c   White, C Michael ^b,c  

^a UNIVERSITY OF CONNECTICUT   (United States)

^b UNIVERSITY OF CONNECTICUT   (United States)

^c HARTFORD HOSPITAL   (United States)

Author keywords

Coenzyme Q10; Electrocardiographic effects; Hemodynamic effects; Ubiquinone

Indexed keywords

PLACEBO; STATINE DERIVATIVE; UBIDECARENONE;

ACTION POTENTIAL; ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ELECTROCARDIOGRAPHY; ENERGY YIELD; ESSENTIAL HYPERTENSION; FEMALE; GUINEA PIG; HEART FAILURE; HEART INDEX; HEMODYNAMICS; HUMAN; HUMAN EXPERIMENT; IMPEDANCE; IMPEDANCE CARDIOGRAPHY; MALE; MITOCHONDRIAL ENERGY TRANSFER; MYOPATHY; NORMAL HUMAN; P WAVE; PR INTERVAL; PRIORITY JOURNAL; QRS COMPLEX; QT INTERVAL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; RR INTERVAL; SINGLE DRUG DOSE; SYSTEMIC VASCULAR RESISTANCE; SYSTOLIC BLOOD PRESSURE;

ADULT; BLOOD PRESSURE; CROSS-OVER STUDIES; DIETARY SUPPLEMENTS; DOUBLE-BLIND METHOD; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; MALE; UBIQUINONE; VITAMINS;

EID: 34047234904     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1H539     Document Type: Article

References (22)

1. Barnes PM, Powell-Griner E, McFann K, Nahin RL. Complementary and alternative medicine use among adults: United States, 2002. Advance data from vital and health statistics; no 343. Hyattsville, MD: National Center for Health Statistics, 2004
2. Guidance for Industry. Clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. Rockville, MD: Food and Drug Administration, October 2005.
3. Tran MT, Mitchell TM, Kennedy DT, Giles JT. Role of coenzyme Q10 in chronic heart failure, angina, and hypertension. Pharmacotherapy 2001;21:797-806.
4. Shults CW, Oakes D, Kieburtz K, et al. Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol 2002;59:1541-50.
5. Conklin KA. Coenzyme Q10 for prevention of anthracycline-induced cardiotoxicity. Integr Cancer Ther 2005;4:110-30.
6. Arita M, Nakamura S, Kiyosue T. Effects of coenzyme Q10 on action potentials and ionic currents in isolated ventricular myocytes: possible blockade of ATP-regulated K channels. In: Folkers K, Yamamura Y, eds. Biomedical and clinical aspects of coenzyme Q. Vol. 5. Amsterdam, Netherlands: Elsevier, 1986:131-43.
7. Takasawa K, Fuse K, Konishi T, Watanabe Y, Kobayashi T, Konishi H. Prevention of premature ventricular contractions with CoQ10 after coronary artery bypass grafting. In: Folkers K, Littarru GP, Yamagami T, eds. Biomedical and clinical aspects of coenzyme Q. Amsterdam, Netherlands: Elsevier, 1991:493-7.
8. Lu W, Zhang Q, Lee H, et al. Total coenzyme Q10 concentrations in Asian men following multiple oral 50-mg doses administered as coenzyme Q10 sustained release tablets or regular tablets. Biol Pharm Bull 2003;26:52-5.
9. Perloff D, Grim C, Flack J, et al. Human blood pressure determination by sphygmomanometry. Circulation 1993;88:2460-7.
10. Albert NM, Hail MD, Li J, Young JB. Equivalence of the bioimpedance and thermodilution methods in measuring cardiac output in hospitalized patients with advanced, decompensated chronic heart failure. Am J Crit Care 2004;13:469-79.
11. Terra SG, Blum RA, Wei GC, et al. Evaluation of methods for improving precision of blood pressure measurements in phase I clinical trials. J Clin Pharmacol 2004;44:457-63.
12. Molnar J, Shang F, Weiss J, Ehlert FA, Rosenthal JE. Diurnal pattern of QTc interval: how long is prolonged? Possible relation to circadian triggers of cardiovascular events. J Am Coll Cardiol 1996;27:76-83.
13. Corea L, Cardoni O, Fogari R, et al. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: a comparative study of the efficacy and safety against amlodipine. Clin Pharmacol Ther 1996;60:341-6.
14. Caron MF, Hotsko AL, Robertson S, Mandybur L, Kluger J, White CM. Electrocardiographic and hemodynamic effects of Panax ginseng. Ann Pharmacother 2002;36:758-63. DOI 10.1345/aph.1A411
15. Hodgson JM, Watts GF. Can coenzyme Q10 improve vascular function and blood pressure? Potential for effective therapeutic reduction in vascular oxidative stress. Biofactors 2003;18:129-36.
16. Gentile S, Cacciapuoti F, Buonocore S, Paolisso G, Varricchio M. Usefulness of coenzyme Q10 in suppressing ventricular arrhythmias in post-myocardial infarction patients. In: Folkers K, Littarru GP, Yamagami T, eds. Biomedical and clinical aspects of coenzyme Q. Amsterdam, Netherlands: Elsevier, 1991:493-7.
17. Morisco C, Trimarco B, Condorelli M. Effect of coenzyme Q10 therapy in patients with congestive heart failure: a long-term multicenter randomized study. Clin Invest 1993;71(suppl):S134-6.
18. Yamagami T, Takagi M, Akagami H, et al. Effects of coenzyme Q10 on essential hypertension: a double blind controlled study. In: Folkers K, Yamamura Y eds. Biomedical and clinical aspects of coenzyme Q. Vol. 5. Amsterdam, Netherlands: Elsevier, 1986:131-43.
19. Rosenfeldt F, Hilton D, Pepe S, Krum H. Systematic review of effect of coenzyme Q10 in physical exercise, hypertension and heart failure. Biofactors 2003;18:91-100.
20. Jones PP, Christou DD, Jordan J, Seals DR. Baroreflex buffering is reduced with age in healthy men. Circulation 2003;107:1770-4.
21. Soja AM, Mortensen SA. Treatment of congestive heart failure with coenzyme Q10 illuminated by meta-analyses of clinical trials. Mol Aspects Med 1997;18(suppl):S159-68.
22. Greenberg S, Frishman WH. Co-enzyme Q10: a new drug for cardiovascular disease. J Clin Pharmacol 1990;30:596-608.